Shanghai MicuRx Pharmaceutical (SHA:688373), a US subsidiary of Shanghai MicuRx Pharmaceutical, has filed a lawsuit against Medpace in an Ohio federal court over alleged contract breaches related to a clinical trial agreement, according to a Wednesday filing with the Shanghai bourse.
The dispute stems from Medpace's failure to meet agreed targets and refusal to return trial data. While a partial settlement was reached, unresolved claims remain, the filing said.
The financial impact is uncertain, and the case has yet to go to trial.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。